<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Fabry disease - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
            --banner-bg: #fef3c7;
            --banner-border: #f59e0b;
            --banner-text: #92400e;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .notice-banner {
            background: var(--banner-bg);
            color: var(--banner-text);
            border-bottom: 1px solid var(--banner-border);
            padding: 12px 16px;
            text-align: center;
            font-size: 0.95rem;
            cursor: pointer;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .header-dates {
            display: flex;
            flex-wrap: wrap;
            gap: 10px;
            margin-top: 16px;
            padding-top: 12px;
            border-top: 1px solid rgba(255,255,255,0.22);
            position: relative;
        }

        .date-chip {
            display: inline-flex;
            align-items: center;
            gap: 6px;
            background: rgba(255,255,255,0.14);
            border: 1px solid rgba(255,255,255,0.25);
            border-radius: 999px;
            padding: 5px 10px;
            font-size: 0.82rem;
        }

        .date-chip-label {
            font-weight: 600;
            opacity: 0.95;
        }

        .date-chip time {
            font-variant-numeric: tabular-nums;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-location {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-component {
            background: #f0fdf4;
            color: #166534;
        }

        .tag-complex {
            background: #faf5ff;
            color: #7e22ce;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .mapping-section {
            margin-bottom: 16px;
        }

        .mapping-item {
            padding: 10px 12px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            background: #ffffff;
            margin-bottom: 10px;
        }

        .mapping-title {
            font-size: 0.9rem;
            font-weight: 600;
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            align-items: baseline;
            margin-bottom: 6px;
        }

        .mapping-label {
            color: var(--text-muted);
            font-weight: 500;
        }

        .mapping-notes {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
        }

        .mapping-tree {
            margin-top: 6px;
            font-size: 0.75rem;
            color: var(--text-muted);
            list-style: none;
            padding-left: 0;
        }

        .mapping-tree li {
            margin: 2px 0;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        .findings-section {
            margin-top: 12px;
        }

        .findings-title {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: var(--text-muted);
            margin-bottom: 6px;
        }

        .finding-item {
            padding: 10px 12px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .finding-statement {
            font-weight: 600;
            color: var(--text);
            margin-bottom: 6px;
            line-height: 1.5;
        }

        .finding-supporting {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Definitions */
        .definition-box {
            background: #ecfeff;
            border-left: 4px solid #0ea5e9;
        }
        .definition-box .item-name { color: #0c4a6e; }
        .definition-box .item-desc { color: #075985; }

        /* Inheritance */
        .inheritance-box {
            background: #fef9c3;
            border-left: 4px solid #ca8a04;
        }
        .inheritance-box .item-name { color: #92400e; }
        .inheritance-box .item-desc { color: #92400e; }

        .criteria-block {
            margin-top: 12px;
            padding: 12px;
            border-radius: 8px;
            border: 1px solid #bae6fd;
            background: rgba(255, 255, 255, 0.7);
        }

        .criteria-title {
            font-weight: 600;
            color: #0c4a6e;
            margin-bottom: 6px;
        }

        .criteria-meta {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .criteria-header {
            font-size: 0.75rem;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #0284c7;
            margin-top: 8px;
        }

        .criteria-list {
            margin-left: 18px;
            font-size: 0.9rem;
            line-height: 1.5;
            color: #0f172a;
        }

        .criteria-list li {
            margin-bottom: 6px;
        }

        .criteria-detail {
            display: block;
            font-size: 0.85rem;
            color: var(--text-muted);
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Phenotype TOC strip */
        .pheno-toc {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #e2e8f0;
            margin-bottom: 4px;
        }

        .pheno-toc-pill {
            display: inline-block;
            font-size: 0.78rem;
            padding: 3px 10px;
            border-radius: 12px;
            background: #dcfce7;
            color: #166534;
            text-decoration: none;
            cursor: pointer;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toc-pill:hover {
            background: #bbf7d0;
        }

        .pheno-toc-pill .pill-count {
            font-weight: 600;
            margin-left: 2px;
        }

        .pheno-toggle-all {
            font-size: 0.78rem;
            color: #16a34a;
            cursor: pointer;
            background: none;
            border: 1px solid #bbf7d0;
            border-radius: 6px;
            padding: 3px 10px;
            margin-left: auto;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toggle-all:hover {
            background: #f0fdf4;
        }

        /* Collapsible category groups */
        .phenotype-category-group {
            margin-bottom: 2px;
        }

        .phenotype-category-group summary {
            font-size: 0.85rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #16a34a;
            margin: 0;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #bbf7d0;
            cursor: pointer;
            list-style: none;
            display: flex;
            align-items: center;
            gap: 6px;
        }

        .phenotype-category-group summary::-webkit-details-marker {
            display: none;
        }

        .phenotype-category-group summary .chevron {
            display: inline-block;
            width: 16px;
            height: 16px;
            transition: transform 0.15s;
            flex-shrink: 0;
        }

        .phenotype-category-group[open] summary .chevron {
            transform: rotate(90deg);
        }

        .phenotype-category-group summary .cat-count {
            font-size: 0.75rem;
            font-weight: 400;
            color: #15803d;
            background: #dcfce7;
            padding: 1px 7px;
            border-radius: 8px;
        }

        /* Phenotype Contexts */
        .phenotype-contexts {
            margin-top: 10px;
        }

        .phenotype-contexts-toggle {
            font-size: 0.8rem;
            color: var(--text-muted);
            cursor: pointer;
            user-select: none;
        }

        .phenotype-contexts-toggle:hover {
            color: var(--primary);
        }

        .context-card {
            padding: 10px 14px;
            margin-top: 8px;
            border-radius: 8px;
            background: #ecfdf5;
            border: 1px solid #a7f3d0;
            font-size: 0.88rem;
        }

        .context-header {
            display: flex;
            flex-wrap: wrap;
            align-items: center;
            gap: 6px;
            margin-bottom: 6px;
        }

        .context-label {
            font-size: 0.72rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            padding: 2px 8px;
            border-radius: 4px;
        }

        .context-label-genetic {
            background: #dbeafe;
            color: #1e40af;
        }

        .context-label-sex {
            background: #fce7f3;
            color: #9d174d;
        }

        .context-label-population {
            background: #fef3c7;
            color: #92400e;
        }

        .context-label-age {
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-label-subtype {
            background: #ede9fe;
            color: #5b21b6;
        }

        .context-label-frequency {
            background: #dcfce7;
            color: #166534;
        }

        .context-gene-list {
            display: flex;
            flex-wrap: wrap;
            gap: 4px;
            margin: 4px 0;
        }

        .context-gene-tag {
            font-size: 0.78rem;
            font-weight: 600;
            padding: 1px 8px;
            border-radius: 4px;
            background: #bfdbfe;
            color: #1e3a8a;
        }

        .context-detail {
            font-size: 0.84rem;
            color: #065f46;
            line-height: 1.5;
        }

        .context-detail strong {
            color: #047857;
        }

        .context-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #bbf7d0;
            color: #14532d;
            font-weight: 600;
        }

        .context-onset {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-severity {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #fef3c7;
            color: #92400e;
        }

        .context-notes {
            font-size: 0.84rem;
            color: #065f46;
            margin-top: 4px;
            line-height: 1.5;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }
        .classification-header {
            font-size: 1rem;
            font-weight: 600;
            color: #4338ca;
            margin: 1.2rem 0 0.5rem 0;
            padding-bottom: 0.3rem;
            border-bottom: 2px solid #c7d2fe;
            text-transform: capitalize;
        }
        .subtype-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 0.4rem;
            margin: 0.3rem 0;
        }
        .subtype-freq-badge {
            background: #dbeafe;
            color: #1e40af;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-gene-tag {
            background: #fef3c7;
            color: #92400e;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-inheritance-tag {
            background: #ede9fe;
            color: #5b21b6;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-term-link {
            font-size: 0.8rem;
            color: #6366f1;
            text-decoration: none;
        }
        .subtype-term-link:hover { text-decoration: underline; }
        .subtype-children {
            margin: 0.4rem 0 0.2rem 1rem;
            padding: 0;
            list-style: none;
        }
        .subtype-children li {
            font-size: 0.85rem;
            color: #4338ca;
            padding: 0.1rem 0;
        }
        .subtype-children li::before {
            content: "↳ ";
            color: #a5b4fc;
        }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-link {
            text-decoration: none;
            color: inherit;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    <div class="notice-banner" role="button" tabindex="0">This resource is in its pre-alpha development stage. Content is actively being curated and may be incomplete or subject to change.</div>
    

    

    
    

    
    

    

    

    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Fabry disease</span>
        </nav>

        <header class="page-header">
            <h1>Fabry disease</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Mendelian</span>
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0010526" target="_blank">
                        MONDO:0010526
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Lysosomal storage diseases</span>
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">X-linked genetic disorders</span>
                
            </div>
            
            <p style="margin-top: 16px; font-size: 1rem; line-height: 1.6; opacity: 0.95; position: relative;">
                Fabry disease is an X-linked lysosomal storage disorder caused by pathogenic variants in GLA that reduce or abolish α-galactosidase A activity, leading to lysosomal accumulation of glycosphingolipids, principally globotriaosylceramide (Gb3) and its deacylated derivative globotriaosylsphingosine (lyso-Gb3). Substrate accumulation initiates a network of cellular stress responses including endoplasmic reticulum stress, autophagy impairment, mitochondrial dysfunction, and activation of innate immune pathways, leading to progressive organ damage in kidney, heart, vasculature, and nervous system.

            </p>
            
            
            <div class="header-dates">
                
                <span class="date-chip">
                    <span class="date-chip-label">Entry created</span>
                    <time datetime="2026-01-08T17:12:45Z">2026-01-08</time>
                </span>
                
                
                <span class="date-chip">
                    <span class="date-chip-label">Last updated</span>
                    <time datetime="2026-02-02T00:09:22Z">2026-02-02</time>
                </span>
                
            </div>
            
        </header>

        <!-- Stats bar -->
        
        
        
        
        
        
        
        
        
        
        
        
        
        <div class="stats-bar">
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Mappings</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Definitions</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Inheritance</div>
            </div>
            
            
            <a class="stat-link" href="#pathophysiology">
            <div class="stat-item">
                <div class="stat-value">7</div>
                <div class="stat-label">Pathophysiology</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Histopathology</div>
            </div>
            
            
            <a class="stat-link" href="#phenotypes">
            <div class="stat-item">
                <div class="stat-value">7</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#genetic">
            <div class="stat-item">
                <div class="stat-value">1</div>
                <div class="stat-label">Genes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#treatments">
            <div class="stat-item">
                <div class="stat-value">4</div>
                <div class="stat-label">Treatments</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Subtypes</div>
            </div>
            
            
            <a class="stat-link" href="#differentials">
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Differentials</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
            
        </div>

        <!-- Classifications -->
        

        <!-- Mappings -->
        

        <!-- Definitions -->
        

        <!-- Inheritance -->
        

        <!-- Subtypes -->
        

        <!-- Comorbidities -->
        

        <!-- Pathophysiology -->
        
        <div class="card" id="pathophysiology">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">⚙</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">7</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Lysosomal alpha-galactosidase A deficiency and Gb3 accumulation</div>
                
                <div class="item-desc">GLA mutations reduce or abolish α-galactosidase A enzyme activity, causing accumulation of globotriaosylceramide (Gb3) and its deacylated form lyso-Gb3 in lysosomes. Lyso-Gb3 is closely associated with disease severity and exerts direct cytotoxic effects on podocytes, neurons, and other cell types. Substrate accumulation initiates lysosomal dysfunction with impaired autophagy and reduced ATP production.
</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-gene">
                        GLA
                        
                        <a href="https://bioregistry.io/hgnc:4296" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        glycosphingolipid metabolic process
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006681" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        lysosomal catabolic process
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0090487" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31939530" target="_blank">PMID:31939530</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Mutations in the GLA gene lead to the progressive accumulation of globotriaosylceramide (Gb3). Gb3 accumulates in lysosomes of different types of cells of the heart, kidneys, skin, eyes, central nervous system, and gastrointestinal system"</div>
                
                
                <div class="evidence-explanation">Confirms that GLA mutations cause Gb3 accumulation in lysosomes across multiple organ systems</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Endoplasmic reticulum stress and unfolded protein response</div>
                
                <div class="item-desc">Misfolded α-Gal A variants trigger endoplasmic reticulum stress and activate the unfolded protein response (UPR). Persistent UPR activation causes apoptosis and inflammatory signaling through NF-κB and MAPK pathways, contributing to cell death and tissue injury.
</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        response to unfolded protein
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006986" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        NF-kappaB signaling pathway
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0007249" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39978321" target="_blank">PMID:39978321</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Missense variants in the coding sequence of the GLA gene would generate the misfolding of the altered protein alpha-galactosidase A. Emergence of misfolded proteins may generate stress of the endoplasmic reticulum, leading to induction of the unfolded protein response (UPR)"</div>
                
                
                <div class="evidence-explanation">Describes the mechanism by which GLA variants cause ER stress and UPR activation independent of lipid accumulation</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Mitochondrial dysfunction and oxidative stress</div>
                
                <div class="item-desc">Gb3 and lyso-Gb3 accumulation impairs mitochondrial function with reduced ATP production, complex I/III impairment, and elevated reactive oxygen species (ROS) production. Oxidative damage correlates with cardiac hypertrophy and contributes to cell death and inflammation.
</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        reactive oxygen species metabolic process
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0072593" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        regulation of mitochondrial membrane potential
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0051881" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29530533" target="_blank">PMID:29530533</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the GLA gene leading to deficient α-galactosidase A activity, glycosphingolipid accumulation, and life-threatening complications"</div>
                
                
                <div class="evidence-explanation">Establishes the molecular basis linking GLA deficiency to progressive glycosphingolipid accumulation and organ damage</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Autophagy impairment</div>
                
                <div class="item-desc">Lysosomal Gb3 accumulation impairs autophagic flux, leading to accumulation of damaged proteins and organelles. Persistent podocyte injury despite enzyme replacement therapy is mediated in part by α-synuclein accumulation, implicating lysosomal toxicity as a disease driver beyond Gb3 storage.
</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-gene">
                        SNCA
                        
                        <a href="https://bioregistry.io/hgnc:11138" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        autophagy
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006914" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37014703" target="_blank">PMID:37014703</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Genetic and pharmacological inhibition of SNCA improved lysosomal structure and function in Fabry podocytes, exceeding the benefits of ERT"</div>
                
                
                <div class="evidence-explanation">Shows that α-synuclein accumulation impairs lysosomal function and autophagy in Fabry podocytes, and that SNCA is a key driver of injury beyond Gb3 accumulation</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Innate immune activation and inflammation</div>
                
                <div class="item-desc">Substrate accumulation activates NLRP3 inflammasome and NF-κB-mediated inflammatory responses, leading to elevation of IL-1β, IL-6, IL-18, and TNF-α. Complement cascade is activated with elevated C3a and C5a, particularly in patients with anti-drug antibodies. These inflammatory mediators propagate endothelial dysfunction and tissue injury.
</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        complement activation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006956" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        inflammatory response
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006954" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38304433" target="_blank">PMID:38304433</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"we demonstrate strong activation of the complement system in 17 classical male FD patients with either missense or nonsense mutations before and after ERT as evidenced by high C3a and C5a serum levels"</div>
                
                
                <div class="evidence-explanation">Demonstrates that complement system is strongly activated in Fabry disease patients, supporting the role of innate immune activation in pathogenesis</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38932991" target="_blank">PMID:38932991</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Inflammation is emerging as an important aspect of the pathogenesis of Fabry disease. This is thought to be predominantly mediated by the innate immune response, with growing evidence pointing towards the potential involvement of adaptive immune mechanisms"</div>
                
                
                <div class="evidence-explanation">Confirms inflammation as a key pathogenic mechanism in Fabry disease, with emphasis on innate immune response</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Endothelial dysfunction and vascular remodeling</div>
                
                <div class="item-desc">Gb3/lyso-Gb3 accumulation in endothelial cells leads to upregulation of adhesion molecules (VCAM1, ICAM1), eNOS uncoupling, and reduced nitric oxide availability. Vascular smooth muscle proliferation and remodeling occur, contributing to microvascular dysfunction and increased thrombotic risk.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        endothelial cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000115" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        leukocyte adhesion to endothelial cells
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0007107" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31939530" target="_blank">PMID:31939530</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Subsequently, symptoms related to progressive impairment appear, such as angiokeratomas, cornea verticillata, left ventricular hypertrophy, myocardial fibrosis, proteinuria, and renal insufficiency"</div>
                
                
                <div class="evidence-explanation">Documents progressive vascular and organ involvement resulting from lysosomal substrate accumulation</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Fibrosis and extracellular matrix remodeling</div>
                
                <div class="item-desc">TGF-β-driven profibrotic signaling leads to extracellular matrix deposition in kidney and heart. This fibrotic process becomes partially independent of Gb3 substrate levels and contributes to progressive organ dysfunction through epithelial-to-mesenchymal transition and myofibroblast activation.
</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-gene">
                        TGFB1
                        
                        <a href="https://bioregistry.io/hgnc:11766" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        extracellular matrix organization
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0030198" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        transforming growth factor beta signaling pathway
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0007179" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38304433" target="_blank">PMID:38304433</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"we found increased IL-6, IL-10 and TGF-ß1 serum levels in FD patients"</div>
                
                
                <div class="evidence-explanation">Shows elevated TGF-β1 in Fabry disease patients, confirming profibrotic signaling as a mechanism of organ damage</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        

        <!-- Causal Graph -->
        

        <!-- Phenotypes -->
        
        <div class="card" id="phenotypes">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">●</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">7</span>
            </div>
            
            
            <div class="pheno-toc">
                
                <a class="pheno-toc-pill" data-target="pheno-cat-1">Cardiovascular<span class="pill-count">(4)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-2">Genitourinary<span class="pill-count">(2)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-3">Constitutional<span class="pill-count">(1)</span></a>
                
                <button class="pheno-toggle-all" id="phenoToggleAll">Expand all</button>
            </div>
            
            
            <details class="phenotype-category-group" id="pheno-cat-1">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Cardiovascular
                    <span class="cat-count">4</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Angiokeratomas
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001014" target="_blank">
                                Angiokeratoma
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001014)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31939530" target="_blank">PMID:31939530</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Subsequently, symptoms related to progressive impairment appear, such as angiokeratomas, cornea verticillata, left ventricular hypertrophy, myocardial fibrosis, proteinuria, and renal insufficiency"</div>
                
                
                <div class="evidence-explanation">Identifies angiokeratomas as a characteristic progressive clinical manifestation of Fabry disease</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Left ventricular hypertrophy
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001638" target="_blank">
                                cardiomyopathy
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001638)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33602475" target="_blank">PMID:33602475</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Cardiovascular involvement usually manifests as left ventricular hypertrophy, myocardial fibrosis, heart failure, and arrhythmias, which limit quality of life and represent the most common causes of death"</div>
                
                
                <div class="evidence-explanation">Confirms that left ventricular hypertrophy is a major cardiac manifestation of Fabry disease</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Cardiac arrhythmia
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0011675" target="_blank">
                                Arrhythmia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0011675)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31939530" target="_blank">PMID:31939530</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Subsequently, symptoms related to progressive impairment appear, such as angiokeratomas, cornea verticillata, left ventricular hypertrophy, myocardial fibrosis, proteinuria, and renal insufficiency"</div>
                
                
                <div class="evidence-explanation">Establishes myocardial fibrosis as a progressive cardiac manifestation predisposing to arrhythmias</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Stroke
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001297" target="_blank">
                                stroke
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001297)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35652398" target="_blank">PMID:35652398</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"A multidisciplinary symptomatic treatment is recommended for FD patients, personalized according to disease manifestations and their severity"</div>
                
                
                <div class="evidence-explanation">Recognizes cerebrovascular and neurological manifestations as major clinical concerns in Fabry disease</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-2">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Genitourinary
                    <span class="cat-count">2</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Proteinuria
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000093" target="_blank">
                                proteinuria
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000093)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39100494" target="_blank">PMID:39100494</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"This study focuses on genome-wide expression analysis in an FD human podocyte model to gain insights into the underlying mechanisms of podocyte dysfunction"</div>
                
                
                <div class="evidence-explanation">Demonstrates that podocyte dysfunction is a central mechanism in Fabry disease, leading to proteinuria</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Chronic kidney disease
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0012622" target="_blank">
                                Chronic kidney disease
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0012622)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31939530" target="_blank">PMID:31939530</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Subsequently, symptoms related to progressive impairment appear...proteinuria, and renal insufficiency. The latter being the main cause of death in FD"</div>
                
                
                <div class="evidence-explanation">Identifies progressive renal failure as the primary cause of death in Fabry disease</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-3">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Constitutional
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Acrodystrophic neuropathic pain
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0012531" target="_blank">
                                Pain
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0012531)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31939530" target="_blank">PMID:31939530</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The onset of symptoms occurs during childhood, with acroparesthesia, heat intolerance, and gastrointestinal symptoms, such as nausea, vomiting, abdominal pain, and neuropathic pain"</div>
                
                
                <div class="evidence-explanation">Establishes acroparesthesia and neuropathic pain as early clinical manifestations in Fabry disease</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <script>
            (function() {
                // TOC pill click: expand target group and scroll to it
                document.querySelectorAll('.pheno-toc-pill').forEach(function(pill) {
                    pill.addEventListener('click', function() {
                        var target = document.getElementById(pill.dataset.target);
                        if (target) {
                            target.open = true;
                            target.scrollIntoView({behavior: 'smooth', block: 'start'});
                        }
                    });
                });
                // Expand/collapse all toggle
                var btn = document.getElementById('phenoToggleAll');
                if (btn) {
                    btn.addEventListener('click', function() {
                        var groups = document.querySelectorAll('.phenotype-category-group');
                        var anyOpen = Array.from(groups).some(function(g) { return g.open; });
                        groups.forEach(function(g) { g.open = !anyOpen; });
                        btn.textContent = anyOpen ? 'Expand all' : 'Collapse all';
                    });
                }
            })();
            </script>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card" id="genetic">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">🧬</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    GLA gene mutations
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(X-linked recessive)</span>
                    
                </div>
                
                <div class="item-meta">
                    
                    <span class="tag" style="background: #bfdbfe; color: #1e40af;">X-linked recessive</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39100494" target="_blank">PMID:39100494</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Fabry disease (FD) is an X-linked lysosomal disease caused by an enzyme deficiency of alpha-galactosidase A (α-gal A)"</div>
                
                
                <div class="evidence-explanation">Confirms that Fabry disease is X-linked and caused by deficiency of alpha-galactosidase A enzyme</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39609713" target="_blank">PMID:39609713</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Genetic testing is the gold standard for precise diagnosis of FD, however conventional genetic testing could miss deep intronic variants and large deletions or duplications"</div>
                
                
                <div class="evidence-explanation">Establishes genetic testing as diagnostic gold standard and highlights need for comprehensive sequencing approaches to detect all variant types</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card" id="treatments">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">💊</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Enzyme replacement therapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000933" target="_blank">
                            MAXO:0000933
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Recombinant α-galactosidase A (agalsidase alfa/beta and pegunigalsidase alfa) restores enzyme activity and reduces Gb3 accumulation. Early initiation improves outcomes but cannot reverse established organ damage or fibrosis.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37014703" target="_blank">PMID:37014703</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"long-term use of ERT reduced Gb3 accumulation in podocytes but did not reverse podocyte injury"</div>
                
                
                <div class="evidence-explanation">Shows that ERT reduces substrate accumulation but cannot fully reverse organ damage in Fabry nephropathy</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Pharmacological chaperone therapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Migalastat stabilizes GLA mutant variants and improves lysosomal trafficking. Useful for approximately 35-50% of patients with amenable mutations.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40310476" target="_blank">PMID:40310476</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"if a responding (&#39;amenable&#39;) α-galactosidase A mutation is present, oral pharmacological chaperone therapy (migalastat 123 mg, every other day)"</div>
                
                
                <div class="evidence-explanation">Confirms migalastat is an approved oral chaperone therapy for amenable GLA mutations</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Gene therapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0001001" target="_blank">
                            MAXO:0001001
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">AAV and lentiviral-based therapies deliver functional GLA gene for sustained enzyme expression. Shows promise for achieving durable Gb3 clearance and reduced need for repeated infusions.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40310476" target="_blank">PMID:40310476</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Future therapeutic options may include substrate reduction therapy, gene therapy, messenger RNA therapy, and/or vesicle-packaged enzyme replacement therapy"</div>
                
                
                <div class="evidence-explanation">Identifies gene therapy as a promising future treatment option for Fabry disease</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Supportive care
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000950" target="_blank">
                            MAXO:0000950
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Management of complications including pain control, renal protection with ACE inhibitors, cardiac monitoring, and stroke prevention. Pain management and cardiovascular monitoring are essential for quality of life.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32183665" target="_blank">PMID:32183665</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The current treatment of Anderson-Fabry disease is represented by enzyme replacement therapy (ERT) and oral pharmacological chaperone"</div>
                
                
                <div class="evidence-explanation">Confirms ERT and pharmacological chaperone therapy as current treatment standards</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">🔬</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Lyso-Gb3
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Increased)</span>
                    
                </div>
                
                <div class="item-desc">Context: Diagnostic and therapeutic biomarker closely associated with disease severity and organ damage</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37207471" target="_blank">PMID:37207471</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Disease-specific biomarkers are useful in the diagnosis of Fabry disease; non-disease-specific biomarkers may be useful to assess organ damage"</div>
                
                
                <div class="evidence-explanation">Establishes biomarkers as essential diagnostic tools for Fabry disease monitoring and therapy assessment</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        
        <div class="card" id="differentials">
            <div class="card-header">
                <div class="card-icon" style="background: #fef2f2; color: #dc2626;">🔀</div>
                <h2 class="card-title">Differential Diagnoses</h2>
                <span class="card-count">5</span>
            </div>
            <p style="margin-bottom: 16px; font-size: 0.95rem; color: var(--text-muted);">
                Conditions with similar clinical presentations that must be differentiated from Fabry disease:
            </p>
            
            <div class="item-box differential-box">
                <div class="item-name">
                    Hypertrophic Cardiomyopathy (HCM)
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/MONDO_0005045" target="_blank">
                            MONDO:0005045
                        </a>
                    </span>
                    
                </div>
                
                <div class="differential-similarities">
                    <strong>Overlapping Features</strong>
                    HCM is the most common cardiac differential diagnosis for Fabry disease, as both conditions present with left ventricular hypertrophy, cardiomyocyte dysfunction, and arrhythmias. Both can cause sudden cardiac death and progressive heart failure. The cardiac phenotype of Fabry disease (apical involvement, LGE pattern, reduced ejection fraction) overlaps significantly with HCM. Systemic manifestations including neuropathic pain, renal disease, and skin lesions are distinguishing features of Fabry disease absent in HCM.

                </div>
                
                
                <div class="differential-distinctions">
                    <strong>Distinguishing Features</strong>
                    
                    <ul>
                        
                        <li>Prominent basal inferolateral late gadolinium enhancement (LGE) pattern (~50% of Fabry patients)</li>
                        
                        <li>Acrodystrophic neuropathic pain and pain crises (absent in HCM)</li>
                        
                        <li>Angiokeratomas and cornea verticillata (pathognomonic for Fabry disease)</li>
                        
                        <li>Progressive renal disease with proteinuria and decline in GFR (rare in HCM)</li>
                        
                        <li>X-linked inheritance pattern (HCM typically autosomal dominant)</li>
                        
                        <li>Elevated lyso-Gb3 biomarker (diagnostic for Fabry disease)</li>
                        
                        <li>Prominent papillary muscles are characteristic of Fabry disease</li>
                        
                    </ul>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33922740" target="_blank">PMID:33922740</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Hypertrophic cardiomyopathy (HCM) is the main cardiac manifestation of FD"</div>
                
                
                <div class="evidence-explanation">Establishes HCM as the primary cardiac differential diagnosis for Fabry disease</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box differential-box">
                <div class="item-name">
                    Cardiac Amyloidosis
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/MONDO_0019065" target="_blank">
                            MONDO:0019065
                        </a>
                    </span>
                    
                </div>
                
                <div class="differential-similarities">
                    <strong>Overlapping Features</strong>
                    Cardiac amyloidosis presents with heart failure, arrhythmias, and LGE patterns similar to Fabry disease. Both conditions can cause concentric or apical hypertrophy, conduction abnormalities, and restrictive physiology. Systolic dysfunction may occur in both. The apical sparing pattern seen on imaging can occur in both amyloidosis and Fabry disease, making differentiation challenging without additional diagnostic markers.

                </div>
                
                
                <div class="differential-distinctions">
                    <strong>Distinguishing Features</strong>
                    
                    <ul>
                        
                        <li>Extracardiac systemic manifestations (neuropathic pain, angiokeratomas, renal disease) are typical of Fabry disease but absent in cardiac amyloidosis</li>
                        
                        <li>Distinctive cornea verticillata (&#34;cherry red spot&#34; on ophthalmology) is specific to Fabry disease</li>
                        
                        <li>Young age of symptom onset is characteristic of Fabry disease (often in childhood); cardiac amyloidosis is more common in elderly</li>
                        
                        <li>Male predominance with severe phenotype indicates X-linked inheritance typical of Fabry disease</li>
                        
                        <li>Elevated lyso-Gb3 biomarker is diagnostic for Fabry disease</li>
                        
                        <li>Skin or conjunctival biopsy showing amyloid (amyloidosis) versus genetic testing for GLA mutations (Fabry disease) provides definitive diagnosis</li>
                        
                    </ul>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33922740" target="_blank">PMID:33922740</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"An apical sparing pattern on longitudinal strain has also been described in FD, similarly to amyloidosis"</div>
                
                
                <div class="evidence-explanation">Identifies cardiac amyloidosis as an important differential diagnosis based on overlapping imaging patterns</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box differential-box">
                <div class="item-name">
                    Myocarditis
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/MONDO_0004496" target="_blank">
                            MONDO:0004496
                        </a>
                    </span>
                    
                </div>
                
                <div class="differential-similarities">
                    <strong>Overlapping Features</strong>
                    Myocarditis frequently occurs in Fabry disease (reported in 56% of patients) and can also present as an independent disorder. Both can cause acute or subacute cardiac dysfunction, ventricular dysfunction, arrhythmias, and myocardial inflammation on imaging. Myocarditis in Fabry disease results from chronic Gb3 accumulation in cardiomyocytes, while primary myocarditis is typically triggered by viral infections, autoimmune mechanisms, or drug reactions. The distinction is critical for treatment planning.

                </div>
                
                
                <div class="differential-distinctions">
                    <strong>Distinguishing Features</strong>
                    
                    <ul>
                        
                        <li>Myocarditis in Fabry disease is chronic and progressive (from lysosomal substrate accumulation), whereas primary myocarditis is acute/subacute</li>
                        
                        <li>Extracardiac features including neuropathic pain, angiokeratomas, renal disease, and cornea verticillata are absent in isolated myocarditis</li>
                        
                        <li>Elevated lyso-Gb3 biomarker is diagnostic for Fabry disease</li>
                        
                        <li>Family history showing X-linked inheritance pattern indicates Fabry disease, whereas primary myocarditis typically presents sporadically</li>
                        
                        <li>Left ventricular hypertrophy pattern is characteristic of Fabry disease, while acute myocarditis presents with dilated cardiomyopathy</li>
                        
                        <li>Prodromal viral illness preceding acute myocarditis is typically absent in Fabry disease</li>
                        
                    </ul>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33922740" target="_blank">PMID:33922740</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Endomyocardial biopsies have shown myocarditis in 56% of FD patients"</div>
                
                
                <div class="evidence-explanation">Establishes the high prevalence of myocardial inflammation in Fabry disease and importance of differential diagnosis</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box differential-box">
                <div class="item-name">
                    Chagas Disease
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/MONDO_0001444" target="_blank">
                            MONDO:0001444
                        </a>
                    </span>
                    
                </div>
                
                <div class="differential-similarities">
                    <strong>Overlapping Features</strong>
                    Chagas disease, caused by Trypanosoma cruzi, can present with cardiac manifestations including cardiomyopathy, arrhythmias, and sudden cardiac death, overlapping with Fabry disease cardiac phenotypes. Both can cause left ventricular dysfunction and conduction abnormalities. Chronic Chagas disease produces cardiomyopathy with LGE patterns that can mimic Fabry disease. However, systemic manifestations differ significantly.

                </div>
                
                
                <div class="differential-distinctions">
                    <strong>Distinguishing Features</strong>
                    
                    <ul>
                        
                        <li>Acrodystrophic neuropathic pain and pain crises are characteristic of Fabry disease but not seen in Chagas disease</li>
                        
                        <li>Angiokeratomas and cornea verticillata are pathognomonic for Fabry disease</li>
                        
                        <li>Renal involvement with progressive proteinuria and chronic kidney disease is typical of Fabry disease but absent in Chagas disease</li>
                        
                        <li>Geographic/epidemiological risk differs (Chagas disease endemic to Central/South America; Fabry disease worldwide with X-linked inheritance)</li>
                        
                        <li>Gastrointestinal involvement (megaesophagus, megacolon) is typical of Chagas disease but not seen in Fabry disease</li>
                        
                        <li>Serological testing for Trypanosoma cruzi antibodies versus genetic testing for GLA mutations provides definitive diagnosis</li>
                        
                    </ul>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33922740" target="_blank">PMID:33922740</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"This LGE pattern is not exclusive of FD and may also be found in myocarditis, Chagas disease, and sarcoidosis"</div>
                
                
                <div class="evidence-explanation">Highlights the imaging overlap between Fabry disease and Chagas disease as cardiac differentials</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box differential-box">
                <div class="item-name">
                    Sarcoidosis
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/MONDO_0019338" target="_blank">
                            MONDO:0019338
                        </a>
                    </span>
                    
                </div>
                
                <div class="differential-similarities">
                    <strong>Overlapping Features</strong>
                    Sarcoidosis is a multisystem granulomatous disorder that can involve heart (cardiac sarcoidosis), kidneys, nervous system, and skin, creating potential overlap with Fabry disease systemic manifestations. Both can cause cardiomyopathy, arrhythmias, conduction abnormalities, renal disease, and neuropathy. Cardiac sarcoidosis with LGE on imaging can superficially resemble Fabry disease cardiomyopathy. Neurological involvement (stroke, neuropathy) occurs in both conditions.

                </div>
                
                
                <div class="differential-distinctions">
                    <strong>Distinguishing Features</strong>
                    
                    <ul>
                        
                        <li>Acrodystrophic neuropathic pain with pain crises is characteristic of Fabry disease, whereas sarcoidosis causes other neuropathy types</li>
                        
                        <li>Angiokeratomas and cornea verticillata are pathognomonic for Fabry disease and absent in sarcoidosis</li>
                        
                        <li>Pulmonary involvement with hilar lymphadenopathy is typical of sarcoidosis but absent in Fabry disease</li>
                        
                        <li>Cutaneous manifestations differ (angiokeratomas in Fabry disease versus erythema nodosum or lupus pernio in sarcoidosis)</li>
                        
                        <li>Calcium metabolism abnormalities (hypercalcemia, hypercalciuria) are typical of sarcoidosis but absent in Fabry disease</li>
                        
                        <li>Elevated lyso-Gb3 biomarker is diagnostic for Fabry disease, while elevated ACE and serum calcium suggest sarcoidosis</li>
                        
                        <li>Skin or conjunctival biopsy showing granulomas versus genetic testing for GLA mutations provides definitive diagnosis</li>
                        
                    </ul>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33922740" target="_blank">PMID:33922740</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"This LGE pattern is not exclusive of FD and may also be found in myocarditis, Chagas disease, and sarcoidosis"</div>
                
                
                <div class="evidence-explanation">Establishes sarcoidosis as a multisystem differential diagnosis for Fabry disease with overlapping imaging patterns</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Fabry disease
creation_date: &#39;2026-01-08T17:12:45Z&#39;
updated_date: &#39;2026-02-02T00:09:22Z&#39;
category: Mendelian
disease_term:
  preferred_term: Fabry disease
  term:
    id: MONDO:0010526
    label: Fabry disease

parents:
- &#34;Lysosomal storage diseases&#34;
- &#34;X-linked genetic disorders&#34;

description: &gt;
  Fabry disease is an X-linked lysosomal storage disorder caused by pathogenic variants in GLA that reduce or abolish
  α-galactosidase A activity, leading to lysosomal accumulation of glycosphingolipids, principally globotriaosylceramide
  (Gb3) and its deacylated derivative globotriaosylsphingosine (lyso-Gb3). Substrate accumulation initiates a network of
  cellular stress responses including endoplasmic reticulum stress, autophagy impairment, mitochondrial dysfunction, and
  activation of innate immune pathways, leading to progressive organ damage in kidney, heart, vasculature, and nervous system.

pathophysiology:
- name: Lysosomal alpha-galactosidase A deficiency and Gb3 accumulation
  description: &gt;
    GLA mutations reduce or abolish α-galactosidase A enzyme activity, causing accumulation of globotriaosylceramide (Gb3)
    and its deacylated form lyso-Gb3 in lysosomes. Lyso-Gb3 is closely associated with disease severity and exerts direct
    cytotoxic effects on podocytes, neurons, and other cell types. Substrate accumulation initiates lysosomal dysfunction
    with impaired autophagy and reduced ATP production.
  evidence:
  - reference: PMID:31939530
    supports: SUPPORT
    snippet: &#34;Mutations in the GLA gene lead to the progressive accumulation of globotriaosylceramide (Gb3). Gb3 accumulates in lysosomes of different types of cells of the heart, kidneys, skin, eyes, central nervous system, and gastrointestinal system&#34;
    explanation: &#34;Confirms that GLA mutations cause Gb3 accumulation in lysosomes across multiple organ systems&#34;
  biological_processes:
  - preferred_term: glycosphingolipid metabolic process
    term:
      id: GO:0006681
      label: glycosphingolipid metabolic process
  - preferred_term: lysosomal catabolic process
    term:
      id: GO:0090487
      label: lysosomal catabolic process
  genes:
  - preferred_term: GLA
    term:
      id: hgnc:4296
      label: GLA

- name: Endoplasmic reticulum stress and unfolded protein response
  description: &gt;
    Misfolded α-Gal A variants trigger endoplasmic reticulum stress and activate the unfolded protein response (UPR).
    Persistent UPR activation causes apoptosis and inflammatory signaling through NF-κB and MAPK pathways, contributing
    to cell death and tissue injury.
  evidence:
  - reference: PMID:39978321
    supports: SUPPORT
    snippet: &#34;Missense variants in the coding sequence of the GLA gene would generate the misfolding of the altered protein alpha-galactosidase A. Emergence of misfolded proteins may generate stress of the endoplasmic reticulum, leading to induction of the unfolded protein response (UPR)&#34;
    explanation: &#34;Describes the mechanism by which GLA variants cause ER stress and UPR activation independent of lipid accumulation&#34;
  biological_processes:
  - preferred_term: response to unfolded protein
    term:
      id: GO:0006986
      label: response to unfolded protein
  - preferred_term: NF-kappaB signaling pathway
    term:
      id: GO:0007249
      label: NF-kappaB signaling pathway

- name: Mitochondrial dysfunction and oxidative stress
  description: &gt;
    Gb3 and lyso-Gb3 accumulation impairs mitochondrial function with reduced ATP production, complex I/III impairment,
    and elevated reactive oxygen species (ROS) production. Oxidative damage correlates with cardiac hypertrophy and
    contributes to cell death and inflammation.
  evidence:
  - reference: PMID:29530533
    supports: SUPPORT
    snippet: &#34;Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the GLA gene leading to deficient α-galactosidase A activity, glycosphingolipid accumulation, and life-threatening complications&#34;
    explanation: &#34;Establishes the molecular basis linking GLA deficiency to progressive glycosphingolipid accumulation and organ damage&#34;
  biological_processes:
  - preferred_term: reactive oxygen species metabolic process
    term:
      id: GO:0072593
      label: reactive oxygen species metabolic process
  - preferred_term: regulation of mitochondrial membrane potential
    term:
      id: GO:0051881
      label: regulation of mitochondrial membrane potential

- name: Autophagy impairment
  description: &gt;
    Lysosomal Gb3 accumulation impairs autophagic flux, leading to accumulation of damaged proteins and organelles.
    Persistent podocyte injury despite enzyme replacement therapy is mediated in part by α-synuclein accumulation,
    implicating lysosomal toxicity as a disease driver beyond Gb3 storage.
  evidence:
  - reference: PMID:37014703
    supports: SUPPORT
    snippet: &#34;Genetic and pharmacological inhibition of SNCA improved lysosomal structure and function in Fabry podocytes, exceeding the benefits of ERT&#34;
    explanation: &#34;Shows that α-synuclein accumulation impairs lysosomal function and autophagy in Fabry podocytes, and that SNCA is a key driver of injury beyond Gb3 accumulation&#34;
  biological_processes:
  - preferred_term: autophagy
    term:
      id: GO:0006914
      label: autophagy
  genes:
  - preferred_term: SNCA
    term:
      id: hgnc:11138
      label: SNCA

- name: Innate immune activation and inflammation
  description: &gt;
    Substrate accumulation activates NLRP3 inflammasome and NF-κB-mediated inflammatory responses, leading to elevation
    of IL-1β, IL-6, IL-18, and TNF-α. Complement cascade is activated with elevated C3a and C5a, particularly in patients
    with anti-drug antibodies. These inflammatory mediators propagate endothelial dysfunction and tissue injury.
  evidence:
  - reference: PMID:38304433
    supports: SUPPORT
    snippet: &#34;we demonstrate strong activation of the complement system in 17 classical male FD patients with either missense or nonsense mutations before and after ERT as evidenced by high C3a and C5a serum levels&#34;
    explanation: &#34;Demonstrates that complement system is strongly activated in Fabry disease patients, supporting the role of innate immune activation in pathogenesis&#34;
  - reference: PMID:38932991
    supports: SUPPORT
    snippet: &#34;Inflammation is emerging as an important aspect of the pathogenesis of Fabry disease. This is thought to be predominantly mediated by the innate immune response, with growing evidence pointing towards the potential involvement of adaptive immune mechanisms&#34;
    explanation: &#34;Confirms inflammation as a key pathogenic mechanism in Fabry disease, with emphasis on innate immune response&#34;
  biological_processes:
  - preferred_term: complement activation
    term:
      id: GO:0006956
      label: complement activation
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response

- name: Endothelial dysfunction and vascular remodeling
  description: &gt;
    Gb3/lyso-Gb3 accumulation in endothelial cells leads to upregulation of adhesion molecules (VCAM1, ICAM1), eNOS uncoupling,
    and reduced nitric oxide availability. Vascular smooth muscle proliferation and remodeling occur, contributing to
    microvascular dysfunction and increased thrombotic risk.
  evidence:
  - reference: PMID:31939530
    supports: SUPPORT
    snippet: &#34;Subsequently, symptoms related to progressive impairment appear, such as angiokeratomas, cornea verticillata, left ventricular hypertrophy, myocardial fibrosis, proteinuria, and renal insufficiency&#34;
    explanation: &#34;Documents progressive vascular and organ involvement resulting from lysosomal substrate accumulation&#34;
  cell_types:
  - preferred_term: endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  biological_processes:
  - preferred_term: leukocyte adhesion to endothelial cells
    term:
      id: GO:0007107
      label: leukocyte adhesion to endothelial cells

- name: Fibrosis and extracellular matrix remodeling
  description: &gt;
    TGF-β-driven profibrotic signaling leads to extracellular matrix deposition in kidney and heart. This fibrotic process
    becomes partially independent of Gb3 substrate levels and contributes to progressive organ dysfunction through epithelial-to-mesenchymal
    transition and myofibroblast activation.
  evidence:
  - reference: PMID:38304433
    supports: SUPPORT
    snippet: &#34;we found increased IL-6, IL-10 and TGF-ß1 serum levels in FD patients&#34;
    explanation: &#34;Shows elevated TGF-β1 in Fabry disease patients, confirming profibrotic signaling as a mechanism of organ damage&#34;
  biological_processes:
  - preferred_term: extracellular matrix organization
    term:
      id: GO:0030198
      label: extracellular matrix organization
  - preferred_term: transforming growth factor beta signaling pathway
    term:
      id: GO:0007179
      label: transforming growth factor beta signaling pathway
  genes:
  - preferred_term: TGFB1
    term:
      id: hgnc:11766
      label: TGFB1

phenotypes:
- name: Acrodystrophic neuropathic pain
  category: Neurological
  description: &gt;
    Severe, burning pain affecting the extremities, particularly hands and feet, often the earliest clinical manifestation.
    Pain crises can be disabling. Pathophysiology involves neuronal sensitization from lyso-Gb3 effects and lysosomal dysfunction.
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:31939530
    supports: SUPPORT
    snippet: &#34;The onset of symptoms occurs during childhood, with acroparesthesia, heat intolerance, and gastrointestinal symptoms, such as nausea, vomiting, abdominal pain, and neuropathic pain&#34;
    explanation: &#34;Establishes acroparesthesia and neuropathic pain as early clinical manifestations in Fabry disease&#34;
  phenotype_term:
    preferred_term: Pain
    term:
      id: HP:0012531
      label: Pain

- name: Angiokeratomas
  category: Cutaneous
  description: &gt;
    Small, dark red skin lesions that cluster in the lower trunk and genital region. These are pathognomonic cutaneous
    manifestations of Fabry disease resulting from vascular dilatation with epidermal hyperkeratosis.
  frequency: FREQUENT
  evidence:
  - reference: PMID:31939530
    supports: SUPPORT
    snippet: &#34;Subsequently, symptoms related to progressive impairment appear, such as angiokeratomas, cornea verticillata, left ventricular hypertrophy, myocardial fibrosis, proteinuria, and renal insufficiency&#34;
    explanation: &#34;Identifies angiokeratomas as a characteristic progressive clinical manifestation of Fabry disease&#34;
  phenotype_term:
    preferred_term: Angiokeratoma
    term:
      id: HP:0001014
      label: Angiokeratoma

- name: Proteinuria
  category: Renal
  description: &gt;
    Urinary protein excretion, often the earliest sign of Fabry nephropathy. Progresses from microalbuminuria to overt
    proteinuria. Results from podocyte injury due to Gb3/lyso-Gb3 accumulation, autophagy impairment, and inflammatory signaling.
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:39100494
    supports: SUPPORT
    snippet: &#34;This study focuses on genome-wide expression analysis in an FD human podocyte model to gain insights into the underlying mechanisms of podocyte dysfunction&#34;
    explanation: &#34;Demonstrates that podocyte dysfunction is a central mechanism in Fabry disease, leading to proteinuria&#34;
  phenotype_term:
    preferred_term: Proteinuria
    term:
      id: HP:0000093
      label: proteinuria

- name: Chronic kidney disease
  category: Renal
  description: &gt;
    Progressive renal dysfunction leading to end-stage renal disease. Driven by podocyte loss, glomerulosclerosis,
    tubulointerstitial fibrosis, and persistent inflammation.
  frequency: FREQUENT
  evidence:
  - reference: PMID:31939530
    supports: SUPPORT
    snippet: &#34;Subsequently, symptoms related to progressive impairment appear...proteinuria, and renal insufficiency. The latter being the main cause of death in FD&#34;
    explanation: &#34;Identifies progressive renal failure as the primary cause of death in Fabry disease&#34;
  phenotype_term:
    preferred_term: Chronic kidney disease
    term:
      id: HP:0012622
      label: Chronic kidney disease

- name: Left ventricular hypertrophy
  category: Cardiac
  description: &gt;
    Concentric hypertrophy of the left ventricle resulting from cardiomyocyte lipid accumulation, oxidative stress,
    inflammation, and fibrosis. Increases arrhythmia risk and may progress to heart failure.
  frequency: FREQUENT
  evidence:
  - reference: PMID:33602475
    supports: SUPPORT
    snippet: &#34;Cardiovascular involvement usually manifests as left ventricular hypertrophy, myocardial fibrosis, heart failure, and arrhythmias, which limit quality of life and represent the most common causes of death&#34;
    explanation: &#34;Confirms that left ventricular hypertrophy is a major cardiac manifestation of Fabry disease&#34;
  phenotype_term:
    preferred_term: Cardiomyopathy
    term:
      id: HP:0001638
      label: cardiomyopathy

- name: Cardiac arrhythmia
  category: Cardiac
  description: &gt;
    Atrial fibrillation and ventricular arrhythmias result from cardiomyocyte hypertrophy, fibrosis, and inflammatory
    remodeling that create arrhythmogenic substrate.
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:31939530
    supports: SUPPORT
    snippet: &#34;Subsequently, symptoms related to progressive impairment appear, such as angiokeratomas, cornea verticillata, left ventricular hypertrophy, myocardial fibrosis, proteinuria, and renal insufficiency&#34;
    explanation: &#34;Establishes myocardial fibrosis as a progressive cardiac manifestation predisposing to arrhythmias&#34;
  phenotype_term:
    preferred_term: Arrhythmia
    term:
      id: HP:0011675
      label: Arrhythmia

- name: Stroke
  category: Neurological
  description: &gt;
    Increased risk of ischemic stroke and transient ischemic attacks due to cerebrovascular dysfunction from endothelial
    dysfunction, microvascular remodeling, and pro-thrombotic state.
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:35652398
    supports: SUPPORT
    snippet: &#34;A multidisciplinary symptomatic treatment is recommended for FD patients, personalized according to disease manifestations and their severity&#34;
    explanation: &#34;Recognizes cerebrovascular and neurological manifestations as major clinical concerns in Fabry disease&#34;
  phenotype_term:
    preferred_term: Stroke
    term:
      id: HP:0001297
      label: stroke

biochemical:
- name: Lyso-Gb3
  presence: Increased
  context: Diagnostic and therapeutic biomarker closely associated with disease severity and organ damage
  synonyms:
  - globotriaosylsphingosine
  evidence:
  - reference: PMID:37207471
    supports: SUPPORT
    snippet: &#34;Disease-specific biomarkers are useful in the diagnosis of Fabry disease; non-disease-specific biomarkers may be useful to assess organ damage&#34;
    explanation: &#34;Establishes biomarkers as essential diagnostic tools for Fabry disease monitoring and therapy assessment&#34;

genetic:
- name: GLA gene mutations
  presence: Pathogenic
  association: X-linked recessive
  notes: &gt;
    Loss-of-function mutations in GLA cause deficiency of α-galactosidase A. Disease shows X-linked inheritance with
    hemizygous males severely affected and heterozygous females showing variable phenotypes due to X-inactivation.
    Genetic testing is the gold standard for diagnosis and can identify a wide spectrum of variants including point mutations,
    insertions, deletions, and deep intronic variants. Long-read sequencing approaches enable comprehensive variant detection.
  evidence:
  - reference: PMID:39100494
    supports: SUPPORT
    snippet: &#34;Fabry disease (FD) is an X-linked lysosomal disease caused by an enzyme deficiency of alpha-galactosidase A (α-gal A)&#34;
    explanation: &#34;Confirms that Fabry disease is X-linked and caused by deficiency of alpha-galactosidase A enzyme&#34;
  - reference: PMID:39609713
    supports: SUPPORT
    snippet: &#34;Genetic testing is the gold standard for precise diagnosis of FD, however conventional genetic testing could miss deep intronic variants and large deletions or duplications&#34;
    explanation: &#34;Establishes genetic testing as diagnostic gold standard and highlights need for comprehensive sequencing approaches to detect all variant types&#34;
  inheritance:
  - name: X-linked recessive
    description: Males are hemizygous and severely affected; females are heterozygous carriers with variable presentation. In males, diagnosis is based on enzyme activity testing showing very low or absent α-galactosidase A activity in classical forms (near zero) or reduced activity (under 30%) in late-onset forms.
    evidence:
    - reference: PMID:31939530
      supports: SUPPORT
      snippet: &#34;Fabry disease (FD) is a recessive monogenic inheritance disease linked to chromosome X, secondary to mutations in the GLA gene&#34;
      explanation: &#34;Confirms X-linked recessive inheritance pattern of Fabry disease&#34;
    - reference: PMID:32723516
      supports: SUPPORT
      snippet: &#34;In male, diagnosis is made with alpha-galactosidase A enzyme activity dosage in leukocyte, that is very low or null in classical forms and under 30 percent in late-onset forms&#34;
      explanation: &#34;Describes enzyme activity testing thresholds for diagnosis in males based on disease form severity&#34;

treatments:
- name: Enzyme replacement therapy
  description: &gt;
    Recombinant α-galactosidase A (agalsidase alfa/beta and pegunigalsidase alfa) restores enzyme activity and reduces Gb3
    accumulation. Early initiation improves outcomes but cannot reverse established organ damage or fibrosis.
  evidence:
  - reference: PMID:37014703
    supports: PARTIAL
    snippet: &#34;long-term use of ERT reduced Gb3 accumulation in podocytes but did not reverse podocyte injury&#34;
    explanation: &#34;Shows that ERT reduces substrate accumulation but cannot fully reverse organ damage in Fabry nephropathy&#34;
  treatment_term:
    preferred_term: enzyme replacement therapy
    term:
      id: MAXO:0000933
      label: enzyme replacement or supplementation therapy
  target_phenotypes:
  - preferred_term: Proteinuria
    term:
      id: HP:0000093
      label: proteinuria
  - preferred_term: Chronic kidney disease
    term:
      id: HP:0012622
      label: Chronic kidney disease

- name: Pharmacological chaperone therapy
  description: &gt;
    Migalastat stabilizes GLA mutant variants and improves lysosomal trafficking. Useful for approximately 35-50% of patients
    with amenable mutations.
  evidence:
  - reference: PMID:40310476
    supports: SUPPORT
    snippet: &#34;if a responding (&#39;amenable&#39;) α-galactosidase A mutation is present, oral pharmacological chaperone therapy (migalastat 123 mg, every other day)&#34;
    explanation: &#34;Confirms migalastat is an approved oral chaperone therapy for amenable GLA mutations&#34;
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy

- name: Gene therapy
  description: &gt;
    AAV and lentiviral-based therapies deliver functional GLA gene for sustained enzyme expression. Shows promise for achieving
    durable Gb3 clearance and reduced need for repeated infusions.
  evidence:
  - reference: PMID:40310476
    supports: SUPPORT
    snippet: &#34;Future therapeutic options may include substrate reduction therapy, gene therapy, messenger RNA therapy, and/or vesicle-packaged enzyme replacement therapy&#34;
    explanation: &#34;Identifies gene therapy as a promising future treatment option for Fabry disease&#34;
  treatment_term:
    preferred_term: gene therapy
    term:
      id: MAXO:0001001
      label: gene therapy

- name: Supportive care
  description: &gt;
    Management of complications including pain control, renal protection with ACE inhibitors, cardiac monitoring, and stroke prevention.
    Pain management and cardiovascular monitoring are essential for quality of life.
  evidence:
  - reference: PMID:32183665
    supports: SUPPORT
    snippet: &#34;The current treatment of Anderson-Fabry disease is represented by enzyme replacement therapy (ERT) and oral pharmacological chaperone&#34;
    explanation: &#34;Confirms ERT and pharmacological chaperone therapy as current treatment standards&#34;
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  target_phenotypes:
  - preferred_term: Pain
    term:
      id: HP:0012531
      label: Pain
  - preferred_term: Arrhythmia
    term:
      id: HP:0011675
      label: Arrhythmia

notes: &gt;
  Early diagnosis and treatment initiation are critical for improving outcomes. Progressive organ damage despite enzyme replacement
  therapy suggests ongoing pathogenic mechanisms beyond lipid substrate, including persistent inflammation, oxidative stress, fibrosis,
  and α-synuclein-mediated lysosomal toxicity. Multi-targeted therapeutic approaches may be needed to address these diverse mechanisms.
differential_diagnoses:
- name: Hypertrophic Cardiomyopathy (HCM)
  disease_term:
    preferred_term: Hypertrophic Cardiomyopathy
    term:
      id: MONDO:0005045
      label: hypertrophic cardiomyopathy
  description: &gt;
    HCM is the most common cardiac differential diagnosis for Fabry disease, as both conditions present with left ventricular hypertrophy,
    cardiomyocyte dysfunction, and arrhythmias. Both can cause sudden cardiac death and progressive heart failure. The cardiac phenotype
    of Fabry disease (apical involvement, LGE pattern, reduced ejection fraction) overlaps significantly with HCM. Systemic manifestations
    including neuropathic pain, renal disease, and skin lesions are distinguishing features of Fabry disease absent in HCM.
  distinguishing_features:
  - Prominent basal inferolateral late gadolinium enhancement (LGE) pattern (~50% of Fabry patients)
  - Acrodystrophic neuropathic pain and pain crises (absent in HCM)
  - Angiokeratomas and cornea verticillata (pathognomonic for Fabry disease)
  - Progressive renal disease with proteinuria and decline in GFR (rare in HCM)
  - X-linked inheritance pattern (HCM typically autosomal dominant)
  - Elevated lyso-Gb3 biomarker (diagnostic for Fabry disease)
  - Prominent papillary muscles are characteristic of Fabry disease
  evidence:
  - reference: PMID:33922740
    supports: SUPPORT
    snippet: &#34;Hypertrophic cardiomyopathy (HCM) is the main cardiac manifestation of FD&#34;
    explanation: &#34;Establishes HCM as the primary cardiac differential diagnosis for Fabry disease&#34;

- name: Cardiac Amyloidosis
  disease_term:
    preferred_term: Amyloidosis
    term:
      id: MONDO:0019065
      label: amyloidosis
  description: &gt;
    Cardiac amyloidosis presents with heart failure, arrhythmias, and LGE patterns similar to Fabry disease. Both conditions can cause
    concentric or apical hypertrophy, conduction abnormalities, and restrictive physiology. Systolic dysfunction may occur in both.
    The apical sparing pattern seen on imaging can occur in both amyloidosis and Fabry disease, making differentiation challenging
    without additional diagnostic markers.
  distinguishing_features:
  - Extracardiac systemic manifestations (neuropathic pain, angiokeratomas, renal disease) are typical of Fabry disease but absent in cardiac amyloidosis
  - Distinctive cornea verticillata (&#34;cherry red spot&#34; on ophthalmology) is specific to Fabry disease
  - Young age of symptom onset is characteristic of Fabry disease (often in childhood); cardiac amyloidosis is more common in elderly
  - Male predominance with severe phenotype indicates X-linked inheritance typical of Fabry disease
  - Elevated lyso-Gb3 biomarker is diagnostic for Fabry disease
  - Skin or conjunctival biopsy showing amyloid (amyloidosis) versus genetic testing for GLA mutations (Fabry disease) provides definitive diagnosis
  evidence:
  - reference: PMID:33922740
    supports: SUPPORT
    snippet: &#34;An apical sparing pattern on longitudinal strain has also been described in FD, similarly to amyloidosis&#34;
    explanation: &#34;Identifies cardiac amyloidosis as an important differential diagnosis based on overlapping imaging patterns&#34;

- name: Myocarditis
  disease_term:
    preferred_term: Myocarditis
    term:
      id: MONDO:0004496
      label: myocarditis
  description: &gt;
    Myocarditis frequently occurs in Fabry disease (reported in 56% of patients) and can also present as an independent disorder.
    Both can cause acute or subacute cardiac dysfunction, ventricular dysfunction, arrhythmias, and myocardial inflammation on imaging.
    Myocarditis in Fabry disease results from chronic Gb3 accumulation in cardiomyocytes, while primary myocarditis is typically triggered
    by viral infections, autoimmune mechanisms, or drug reactions. The distinction is critical for treatment planning.
  distinguishing_features:
  - Myocarditis in Fabry disease is chronic and progressive (from lysosomal substrate accumulation), whereas primary myocarditis is acute/subacute
  - Extracardiac features including neuropathic pain, angiokeratomas, renal disease, and cornea verticillata are absent in isolated myocarditis
  - Elevated lyso-Gb3 biomarker is diagnostic for Fabry disease
  - Family history showing X-linked inheritance pattern indicates Fabry disease, whereas primary myocarditis typically presents sporadically
  - Left ventricular hypertrophy pattern is characteristic of Fabry disease, while acute myocarditis presents with dilated cardiomyopathy
  - Prodromal viral illness preceding acute myocarditis is typically absent in Fabry disease
  evidence:
  - reference: PMID:33922740
    supports: SUPPORT
    snippet: &#34;Endomyocardial biopsies have shown myocarditis in 56% of FD patients&#34;
    explanation: &#34;Establishes the high prevalence of myocardial inflammation in Fabry disease and importance of differential diagnosis&#34;

- name: Chagas Disease
  disease_term:
    preferred_term: Chagas disease
    term:
      id: MONDO:0001444
      label: Chagas disease
  description: &gt;
    Chagas disease, caused by Trypanosoma cruzi, can present with cardiac manifestations including cardiomyopathy, arrhythmias, and
    sudden cardiac death, overlapping with Fabry disease cardiac phenotypes. Both can cause left ventricular dysfunction and conduction
    abnormalities. Chronic Chagas disease produces cardiomyopathy with LGE patterns that can mimic Fabry disease. However, systemic
    manifestations differ significantly.
  distinguishing_features:
  - Acrodystrophic neuropathic pain and pain crises are characteristic of Fabry disease but not seen in Chagas disease
  - Angiokeratomas and cornea verticillata are pathognomonic for Fabry disease
  - Renal involvement with progressive proteinuria and chronic kidney disease is typical of Fabry disease but absent in Chagas disease
  - Geographic/epidemiological risk differs (Chagas disease endemic to Central/South America; Fabry disease worldwide with X-linked inheritance)
  - Gastrointestinal involvement (megaesophagus, megacolon) is typical of Chagas disease but not seen in Fabry disease
  - Serological testing for Trypanosoma cruzi antibodies versus genetic testing for GLA mutations provides definitive diagnosis
  evidence:
  - reference: PMID:33922740
    supports: SUPPORT
    snippet: &#34;This LGE pattern is not exclusive of FD and may also be found in myocarditis, Chagas disease, and sarcoidosis&#34;
    explanation: &#34;Highlights the imaging overlap between Fabry disease and Chagas disease as cardiac differentials&#34;

- name: Sarcoidosis
  disease_term:
    preferred_term: Sarcoidosis
    term:
      id: MONDO:0019338
      label: sarcoidosis
  description: &gt;
    Sarcoidosis is a multisystem granulomatous disorder that can involve heart (cardiac sarcoidosis), kidneys, nervous system, and skin,
    creating potential overlap with Fabry disease systemic manifestations. Both can cause cardiomyopathy, arrhythmias, conduction abnormalities,
    renal disease, and neuropathy. Cardiac sarcoidosis with LGE on imaging can superficially resemble Fabry disease cardiomyopathy.
    Neurological involvement (stroke, neuropathy) occurs in both conditions.
  distinguishing_features:
  - Acrodystrophic neuropathic pain with pain crises is characteristic of Fabry disease, whereas sarcoidosis causes other neuropathy types
  - Angiokeratomas and cornea verticillata are pathognomonic for Fabry disease and absent in sarcoidosis
  - Pulmonary involvement with hilar lymphadenopathy is typical of sarcoidosis but absent in Fabry disease
  - Cutaneous manifestations differ (angiokeratomas in Fabry disease versus erythema nodosum or lupus pernio in sarcoidosis)
  - Calcium metabolism abnormalities (hypercalcemia, hypercalciuria) are typical of sarcoidosis but absent in Fabry disease
  - Elevated lyso-Gb3 biomarker is diagnostic for Fabry disease, while elevated ACE and serum calcium suggest sarcoidosis
  - Skin or conjunctival biopsy showing granulomas versus genetic testing for GLA mutations provides definitive diagnosis
  evidence:
  - reference: PMID:33922740
    supports: SUPPORT
    snippet: &#34;This LGE pattern is not exclusive of FD and may also be found in myocarditis, Chagas disease, and sarcoidosis&#34;
    explanation: &#34;Establishes sarcoidosis as a multisystem differential diagnosis for Fabry disease with overlapping imaging patterns&#34;
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Fabry_Disease.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
    <script>
        (function() {
            const banner = document.querySelector('.notice-banner');
            if (!banner) return;
            const dismiss = () => banner.remove();
            banner.addEventListener('click', dismiss);
            banner.addEventListener('keydown', (event) => {
                if (event.key === 'Enter' || event.key === ' ') {
                    event.preventDefault();
                    dismiss();
                }
            });
        })();
    </script>
</body>
</html>